# SGX Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sgx-pharmaceuticals

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.sgxpharma.com
- Total disclosed funding: $77M
- Latest round: Series C (Sep 20, 2000)
- Investors on record: 11

## About

SGX Pharmaceuticals, Inc. is a company focused on providing domain registration services, particularly in the pharmaceutical sector. They specialize in premium domain names, enhancing online presence for businesses in the healthcare industry.Founded in 1998 in San Diego, US, SGX Pharmaceuticals, Inc. specializes in offering domain registration services tailored for the pharmaceutical sector. In July 2008, the company was acquired by Eli Lilly and Company Limited for USD 66.20 mn. The company has completed 4 notable deals since its inception, primarily focusing on enhancing digital marketing for healthcare businesses. Michael Grey serves as the CEO, although no additional information on the founder is available.SGX Pharmaceuticals, Inc. specializes in domain registration services, concentrating on premium domain names relevant to the pharmaceutical industry. Their offerings help businesses establish a strong online presence, facilitating customer engagement and improving marketing strategies. Target customers include pharmaceutical companies, healthcare providers, and e-commerce platforms, with a focus on North America, Europe, and Asia.In 2007, SGX Pharmaceuticals, Inc. reported revenue of USD 34.74 mn with an EBITDA of USD -14.06 mn for the same year. The company generates revenue primarily through the sale of premium domain names, allowing clients to purchase domain names online, either outright or through structured payment plans, facilitating digital identity for businesses in the pharmaceutical sector.The company plans to leverage the funds from its recent acquisition by expanding its offerings in premium domain registration targeting emerging markets in Asia and Europe by 2010. The recent funding from Eli Lilly and Company Limited will support these initiatives, allowing SGX Pharmaceuticals to enhance its product line and market reach in the pharmaceutical domain registration space.

## Funding rounds

- Series C, Sep 20, 2000, $45M — Atlas Venture, Index Ventures, OrbiMed Advisors, Prospect Venture Partners, Sprout Group, Akina, Scale Venture Partners, Apple Tree Partners, Vector Fund Management, Amerindo Investment Advisors, Lumira Ventures
- Series B, Apr 6, 2000, $32M — Atlas Venture, Index Ventures, Prospect Venture Partners, Sprout Group, Akina, Apple Tree Partners

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series B, Series C
- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Series B, Series C
- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series B, Series C
- Sprout Group (https://capitalatlas.ai/funds/sprout-group) — Series B, Series C
- Akina (https://capitalatlas.ai/funds/akina) — Series B, Series C
- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Scale Venture Partners (https://capitalatlas.ai/funds/scale-venture-partners) — Series C
- Vector Fund Management (https://capitalatlas.ai/funds/vector-fund-management) — Series C
- Amerindo Investment Advisors — Series C
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series C